Stock Track | Omnicell Plummets 14.99% Intraday After Q4 Earnings Miss and Weak 2026 Guidance

Stock Track
Feb 05

Omnicell's stock plummeted 14.99% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The healthcare technology provider reported adjusted earnings per share of $0.40 for Q4 2025, missing the analyst consensus estimate of $0.50. While quarterly revenue showed a slight increase, the company posted a GAAP net loss of $2 million, reversing from a profit in the prior-year period.

Investors reacted negatively to both the earnings miss and the company's outlook for fiscal year 2026, which includes adjusted EPS guidance of $1.65 to $1.85, below the consensus estimate of $1.88. The significant selloff reflects disappointment with the quarterly performance and future earnings projections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10